ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
The Clinical Importance Of Selective Inhibitors Of Cox-2 And New Antiinflammatory Agents Without Gastrointestinal Toxicity
Gönen DENİZ*, Şahan SAYGI*
*Doç.Dr., Dept. of Pharmacology, Gülhane Military Medical Academy Faculty of Medicine, Ankara, TURKEY
Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used as analgesic and antiinflammatory agents. But one of the limiting factors in the use of NSAIDs is the rather high incidence of gastrointestinal (GI) side effects which occur as a result of gastric prostaglandin inhibition. Cyclooxygenase (COX) is the principle enzyme in the production of prostaglandins and inhibition of COX is also the primary mechanism of actions of NSAIDs. Two isoforms of COX have been identified:COX-1and COX-2. The prostaglandins that play a vital role in gastric mucosal protection in the GI tract are derived from COX-1.
Recent studies with COX enzymes indicate that the antiinflammatory effects of NSAIDs relate to COX-2 inhibition, whereas the GI side effects relate to COX-1 inhibition. Essentially, currently available NSAIDs inhibit both COX-1 and COX-2. In order to reduce the GI side effects of NSAIDs, selective COX-2 inhibitors have been developed, which inhibit COX-2 isoform in inflammatory tissue but have only limited effect on COX-1 isoform in the stomach.Keywords: Cyclooxygenase 1 and Cyclooxygenase 2
inhibitors, Prostaglandins,
Gastrointestinal toxicityTurkiye Klinikleri J Med Sci 2000, 20:102-106
|
|
|
|
|
